Kiniksa Pharmaceuticals sees strong growth from Arcalyst, aided by Medicare redesign. Learn about 2025 sales outlook & ...

Portfolio Execution. ARCALYST (IL-1α and IL-1β cytokine trap) ARCALYST net product revenue was $137.8 million for the first quarter of 2025.Since launch, more than 3,150 prescribers have written ...

– ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 ...

Potential Positives. ARCALYST® net product revenue showed strong growth, with Q4 2024 revenue reaching $122.5 million and full year 2024 revenue of $417.0 million, indicating a 79% year-over-year ...

ARCALYST (IL-1α and IL-1β cytokine trap) ARCALYST net product revenue was $122.5 million and $417.0 million for the fourth quarter and full year 2024, respectively. Since launch, more than 2,850 ...

The Business Research Company's Arcalyst (rilonacept) Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to ...

Kiniksa reports 2024 ARCALYST revenue of $416.4 million, expecting $560-$580 million for 2025, while remaining cash flow positive.

- ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth -- ARCALYST 2025 net product revenue expected to be $560 - $580 million ...

– ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 ...

– ARCALYST® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 ...

Arcalyst may alter the blood levels of other medicines such as warfarin, which may require dose changes. These medicines are called cytochrome P450 substrates.